Skip to main content
SpringerLink
Log in

Follicle-Stimulating Hormone

  • Chapter
  • First Online:
Pharmaceutical Biotechnology

  • 137k Accesses

Abstract

About 15 % of all couples experience infertility at some time during their reproductive lives. Nowadays, infertility can be treated by the use of assisted reproductive technologies (ART), such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). A common element of these programs is the treatment with follicle-stimulating hormone (FSH) to increase the number of oocytes retrievable for the IVF or ICSI procedure (multifollicular development). Patients suffering from female infertility because of chronic anovulation may also be treated with FSH, then with the aim to achieve monofollicular development.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • De Leeuw R, Mulders J, Voortman G, Rombout F, Damm J, Kloosterboer L (1996) Structure-function relationship of recombinant follicle stimulating hormone (Puregon®). Mol Hum Reprod 2:361–369

    Article  PubMed  Google Scholar 

  • Devroey P, Boostanfar R, Koper NP, Jzerman PI, Mannaerts BMJL, Fauser BC, for the ENGAGE Investigators (2009) A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 24:3063–3072

    Google Scholar 

  • European Public Assessment Report Gonal-F (Follitropin alpha), CPMP/415/95, revision 18, 11-April 2011. European Agency for the Evaluation of Medicinal Products

    Google Scholar 

  • Fauser BCJM, Mannaerts BMJL, Devroey P, Leader A, Boime I, Baird DT (2009) Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum Reprod Update 15:309–321

    Article  PubMed  CAS  Google Scholar 

  • Fauser BCJM, Alper MM, Ledger W, Schoolcraft WB, Zandvliet A, Mannaerts BMJL (2010) Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during controlled ovarian stimulation for in vitro fertilisation. Reprod Biomed Online 21:593–601

    Article  PubMed  CAS  Google Scholar 

  • Howles CM (1996) Genetic engineering of human FSH (Gonal-F®). Hum Reprod Update 2:172–191

    Article  PubMed  CAS  Google Scholar 

  • Mannaerts BMJL, De Leeuw R, Geelen J, Van Ravenstein A, Van Wezenbeek P, Schuurs A, Kloosterboer L (1992) Comparative in vitro and in vivo studies on the biological properties of recombinant human follicle stimulating hormone. Endocrinology 129:2623–2630

    Article  Google Scholar 

  • Matzuk MM, Hsueh AJ, Lapolt P, Tsafriri A, Keene JL, Boime I (1990) The biological role of the carboxy-terminal extension of human chorionic gonadotropin (corrected) beta-subunit. Endocrinology 126:376–383

    Article  PubMed  CAS  Google Scholar 

  • Norman RJ, Zegers-Hochschild F, Salle BS, Elbers J, Heijnen E, Marintcheva-Petrova M, Mannaerts B (2011) Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity. Hum Reprod 26(8):2200–2208

    Article  PubMed  CAS  Google Scholar 

  • Olijve W, de Boer W, Mulders JWM, van Wezenbeek PMGF (1996) Molecular biology and biochemistry of human recombinant follicle stimulating hormone (PuregonR). Mol Hum Reprod 2:371–382

    Article  PubMed  CAS  Google Scholar 

  • Van Wezenbeek P, Draaier J, Van Meel F, Olyve W (1990) Recombinant follicle stimulating hormone. I. Construction, selection and characterization of a cell line. In: Crommelin DJA, Schellekens H (eds) From clone to clinic developments in biotherapy, vol I. Kluwer, Dordrecht, pp 245–251

    Chapter  Google Scholar 

  • Verbost P, Sloot WN, Rose UM, de Leeuw R, Hanssen RGJM, Verheijden GFM (2011) Pharmacologic profiling of corifollitropin alfa, the first developed sustained follicle stimulant. Eur J Pharmacol 651:227–233

    Article  PubMed  CAS  Google Scholar 

  • Voortman G, van de Post J, Schoemaker RC, van Gerwen J (1999) Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (Puregon®) by Pen-injector and syringe. Hum Reprod 14:1698–1702

    Article  PubMed  CAS  Google Scholar 

Further Reading

  • Mannaerts BMJL (2013) Innovative drug development for infertility therapy, Ph.D. thesis, Utrecht, The Netherlands, ISBN 978-90-393-5939-6

    Google Scholar 

  • Seyhan A, Ata B (2011) The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist. Int J Womens Health 3:243–255

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Regulatory Affairs Department, MSD, Molenstraat 110, Oss, 5342 CC, The Netherlands

    Tom Sam Ph.D.

  2. Regulatory Affairs Department, MSD, Oss, The Netherlands

    Renato de Leeuw

  3. Synthon Biopharmaceuticals B.V., Nijmegen, The Netherlands

    Gijs Verheijden Ph.D.

  4. Global CMC Regulatory Affairs – Biologics, MSD, Oss, The Netherlands

    Anneke Koole

Authors
  1. Tom Sam Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Renato de Leeuw
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gijs Verheijden Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anneke Koole
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tom Sam Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Pharmaceutical Sciences, Utrecht University, Utrecht, Utrecht, The Netherlands

    Daan J. A. Crommelin

  2. Department of Pharmaceutical Sciences and Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada

    Robert D. Sindelar

  3. Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, College of Pharmacy, Memphis, Tennessee, USA

    Bernd Meibohm

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Sam, T., de Leeuw, R., Verheijden, G., Koole, A. (2013). Follicle-Stimulating Hormone. In: Crommelin, D., Sindelar, R., Meibohm, B. (eds) Pharmaceutical Biotechnology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6486-0_13

Download citation

Publish with us

Policies and ethics

Search

Navigation